Lenalidomid Biocon (Lenalidomide)

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma cells and dysplastic clones.

• Multiple myeloma: improves progression‑free survival and overall response when used in combination regimens.
• Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission.
• Mantle cell lymphoma: provides disease control in relapsed or refractory cases, often as part of combination therapy.

• Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This leads to modulation of cytokine production, enhanced T‑cell and NK‑cell activity, inhibition of angiogenesis, and direct anti‑proliferative effects on malignant plasma cells.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness.
• Diarrhea: loose stools.
• Nausea: upset stomach.
• Rash: skin redness or itching.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly low neutrophil count.
• Secondary primary malignancies: emergence of new cancers.

Before initiating lenalidomide therapy, several safety considerations should be reviewed.

• Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception.
• Thromboembolism prophylaxis: assess need for anticoagulation in high‑risk patients.
• Renal impairment: monitor kidney function and adjust therapy as needed.
• Hepatic dysfunction: evaluate liver enzymes and watch for toxicity.
• Infection monitoring: be vigilant for signs of infection due to possible neutropenia.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lenalidomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower lenalidomide exposure.
• Anticoagulants (warfarin, DOACs): increased risk of thrombosis or bleeding.
• Immunosuppressants (e.g., cyclosporine): heightened risk of severe cytopenias.

Moderate Interactions (Monitor Closely)

• P‑glycoprotein inhibitors (e.g., quinidine): may raise plasma levels.
• NSAIDs: additive risk of gastrointestinal bleeding.
• Live vaccines: reduced efficacy; avoid during treatment.